The Clinical Research Unit in Clinical Trials (UICEC) of IDIBELL and the Clinical Pharmacology Service of the Bellvitge Hospital have renewed their participation in the Clinical Research Support Platform of the Instituto de Salud Carlos III (Spanish Clinical Research Network, SCReN ).

The aid granted in the last competitive call for platforms from the Instituto de Salud Carlos III (ISCIII) to this unit, with Dra. Pilar Hereu as principal researcher, allows UICEC to remain as one of the 27 clinical research support units that make up the ISCIII platform throughout Spain during the period 2024-2026.

As a novelty, the UICEC IDIBELL on this occasion incorporates the Clinical Research Unit of the Josep Trueta Hospital (UREC-UIC IDIBGI) as an associated unit.

The UICEC is an IDIBELL platform in functional dependence of the Clinical Pharmacology Service. The portfolio of services offered to IDIBELL researchers in the exercise of their functions and legal responsibilities as promoters includes the monitoring of clinical research studies, project management, processing and administrative management, and pharmacovigilance of trials clinical. Since 2021, it has ISO9001:2015 quality certification.

UICEC’s activity has maintained sustained growth in recent years. During 2023, it has provided service to 41 clinical trials and observational studies with medicines, of which 33 are studies led by 25 researchers from the Bellvitge Campus (21 belonging to 10 different services at the Bellvitge Hospital, 3 from the Catalan Institute of Oncology and 1 of the IDIBELL).

The participation of the UICEC in the SCReN platform is an important factor to favor networking and internationalization. Of the 41 clinical trials to which it has provided services, 17 are projects that have been accepted by the SCReN network and 6 are international projects.

Given that SCReN is part of the European Clinical Research Infrastructure Network (ECRIN), the Clinical Research Unit in Clinical Trials currently provides services to two independent international multicenter clinical trials with funding from the H2020 call and with support from ECRIN. On the other hand, it also provides services to international clinical trials of European consortia such as the Vacelerate European consortium, which researches in covid vaccines, and the TRICALS European consortium, which researches in ALS.